STUDY BASICS
Do you have a schizophrenia diagnosis? Are you 18-50 years old? You may be eligible for a research study to examine whether transcranial magnetic stimulation (TMS) can enhance cognition and connectivity in the brain to work alongside clozapine. Compensation is provided.
STUDY PURPOSE
The purpose of this research study is to use intermittent Theta Burst Stimulation (iTBS) to determine whether neurocognition and connectivity in the prefrontal cortex can be modulated in schizophrenia to increase effectiveness of treatment. We know that clozapine is effective in treatment-resistant schizophrenia (TRS), however we have limited treatment strategies for cognitive deficits of TRS, specifically working memory. We know that certain areas of the brain are involved in cognition, but we want to find out how changing function in these areas influences brain function and memory. Eventually, the findings of this study might be useful in influencing treatment strategies.
COULD THIS STUDY BE RIGHT FOR YOU?
Eligible participants:
- Are 18-50 years old
- Have a schizophrenia or schizoaffective diagnosis
- Use a treatment regimen of clozapine
WHAT PARTICIPANTS CAN EXPECT
This study involves clinical interviews, cognitive brain testing with games, fMRI (magnetic resonance imaging) brain scans, and transcranial magnetic stimulation (TMS), or theta burst simulation (TBS). TBS is just a shorter version of TMS.
TBS is a technique to briefly stimulate a region of your brain with a magnetic field that passes through the scalp and skull safely. We will use the MRI brain images to guide the TBS so that the stimulation is in the right place for our study. We will ask you to complete 5 sessions of TBS at each visit, separated by one month. Each time you get TBS, it will last approximately 10 minutes, with 50-minute breaks in between sessions.
IRB: STUDY23050056
- Accelerated Neuromodulation of Prefrontal Circuitry during Clozapine TreatmentMEET THE RESEARCHER
Deepak Sarpal
Deepak K. Sarpal, M.D., completed residency training in psychiatry at The Zucker Hillside Hospital/Zucker School of Medicine at Hofstra/Northwell in 2015. He is currently an Assistant Professor in the Department of Psychiatry at the University of Pittsburgh School of Medicine where he also serves as Medical Director of the Services for the Treatment of Early Psychosis (STEP) clinic at UPMC Western Psychiatric Hospital. His research focuses on clinical outcomes of and novel treatments for psychotic disorders. His work has been supported by the National Institute of Mental Health, Brain & Behavior Research Foundation, and the Pittsburgh Foundation.